Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
STAT3 inhibitor
DRUG CLASS:
STAT3 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
BBI608 (4)
BP1003 (2)
NT-157 (2)
TTI-101 oral (2)
JSI-124 (2)
EC-70124 (1)
INB03 (1)
YHO-1701 (1)
niclosamide (1)
stattic (1)
CM-728 (0)
DUET-101 (0)
DUET-201 (0)
GLG-302 (0)
HJC0152 (0)
NT219 (0)
OPB-111077 (0)
STAT3 inhibitor (0)
sulforafan alfadex (0)
WP1066 (0)
SK&F106615 (0)
iMX-110 (0)
AZD9150 (0)
ACT001 (0)
BS-HH-002.SA (0)
SHR0302 (0)
VT-11CR (0)
BBI608 (4)
BP1003 (2)
NT-157 (2)
TTI-101 oral (2)
JSI-124 (2)
EC-70124 (1)
INB03 (1)
YHO-1701 (1)
niclosamide (1)
stattic (1)
CM-728 (0)
DUET-101 (0)
DUET-201 (0)
GLG-302 (0)
HJC0152 (0)
NT219 (0)
OPB-111077 (0)
STAT3 inhibitor (0)
sulforafan alfadex (0)
WP1066 (0)
SK&F106615 (0)
iMX-110 (0)
AZD9150 (0)
ACT001 (0)
BS-HH-002.SA (0)
SHR0302 (0)
VT-11CR (0)
›
Associations
(21)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
TTI-101 oral
Sensitive: B - Late Trials
TTI-101 oral
Sensitive
:
B
TTI-101 oral
Sensitive: B - Late Trials
TTI-101 oral
Sensitive
:
B
MSI-H/dMMR
Prostate Cancer
MSI-H/dMMR
Prostate Cancer
pembrolizumab + BBI608
Sensitive: C3 – Early Trials
pembrolizumab + BBI608
Sensitive
:
C3
pembrolizumab + BBI608
Sensitive: C3 – Early Trials
pembrolizumab + BBI608
Sensitive
:
C3
EML4-ALK G1202R
Non Small Cell Lung Cancer
EML4-ALK G1202R
Non Small Cell Lung Cancer
ALK inhibitor + STAT3 inhibitor
Sensitive: C3 – Early Trials
ALK inhibitor + STAT3 inhibitor
Sensitive
:
C3
ALK inhibitor + STAT3 inhibitor
Sensitive: C3 – Early Trials
ALK inhibitor + STAT3 inhibitor
Sensitive
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
NT-157
Sensitive: D – Preclinical
NT-157
Sensitive
:
D
NT-157
Sensitive: D – Preclinical
NT-157
Sensitive
:
D
MUC1 overexpression
Pancreatic Ductal Adenocarcinoma
MUC1 overexpression
Pancreatic Ductal Adenocarcinoma
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
STAT3 expression
Gastric Cancer
STAT3 expression
Gastric Cancer
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
NFKB1 expression
Gastric Cancer
NFKB1 expression
Gastric Cancer
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
BBI608
Sensitive: D – Preclinical
BBI608
Sensitive
:
D
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
ASP7487 + NT-157
Sensitive: D – Preclinical
ASP7487 + NT-157
Sensitive
:
D
ASP7487 + NT-157
Sensitive: D – Preclinical
ASP7487 + NT-157
Sensitive
:
D
PTPRD mutation
Squamous Cell Carcinoma of Head and Neck
PTPRD mutation
Squamous Cell Carcinoma of Head and Neck
JSI-124
Sensitive: D – Preclinical
JSI-124
Sensitive
:
D
JSI-124
Sensitive: D – Preclinical
JSI-124
Sensitive
:
D
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
JSI-124
Sensitive: D – Preclinical
JSI-124
Sensitive
:
D
JSI-124
Sensitive: D – Preclinical
JSI-124
Sensitive
:
D
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
PTPRT promoter methylation
Squamous Cell Carcinoma of Head and Neck
stattic
Sensitive: D – Preclinical
stattic
Sensitive
:
D
stattic
Sensitive: D – Preclinical
stattic
Sensitive
:
D
STAT3 mutation
Uterine Cancer
STAT3 mutation
Uterine Cancer
STAT3 inhibitor
Sensitive: D – Preclinical
STAT3 inhibitor
Sensitive
:
D
STAT3 inhibitor
Sensitive: D – Preclinical
STAT3 inhibitor
Sensitive
:
D
STAT3 mutation
Ovarian Cancer
STAT3 mutation
Ovarian Cancer
STAT3 inhibitor
Sensitive: D – Preclinical
STAT3 inhibitor
Sensitive
:
D
STAT3 inhibitor
Sensitive: D – Preclinical
STAT3 inhibitor
Sensitive
:
D
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
niclosamide
Sensitive: D – Preclinical
niclosamide
Sensitive
:
D
niclosamide
Sensitive: D – Preclinical
niclosamide
Sensitive
:
D
ALK rearrangement
Lung Cancer
ALK rearrangement
Lung Cancer
alectinib + YHO-1701
Sensitive: D – Preclinical
alectinib + YHO-1701
Sensitive
:
D
alectinib + YHO-1701
Sensitive: D – Preclinical
alectinib + YHO-1701
Sensitive
:
D
KRAS G12C
Lung Adenocarcinoma
KRAS G12C
Lung Adenocarcinoma
TTI-101 oral
Sensitive: D – Preclinical
TTI-101 oral
Sensitive
:
D
TTI-101 oral
Sensitive: D – Preclinical
TTI-101 oral
Sensitive
:
D
STAT3 expression
Breast Cancer
STAT3 expression
Breast Cancer
BP1003
Sensitive: D – Preclinical
BP1003
Sensitive
:
D
BP1003
Sensitive: D – Preclinical
BP1003
Sensitive
:
D
STAT3 expression
Ovarian Cancer
STAT3 expression
Ovarian Cancer
BP1003
Sensitive: D – Preclinical
BP1003
Sensitive
:
D
BP1003
Sensitive: D – Preclinical
BP1003
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
EC-70124
Sensitive: D – Preclinical
EC-70124
Sensitive
:
D
EC-70124
Sensitive: D – Preclinical
EC-70124
Sensitive
:
D
BRAF mutation
Melanoma
BRAF mutation
Melanoma
PD1 inhibitor + STAT3 inhibitor
Sensitive: D – Preclinical
PD1 inhibitor + STAT3 inhibitor
Sensitive
:
D
PD1 inhibitor + STAT3 inhibitor
Sensitive: D – Preclinical
PD1 inhibitor + STAT3 inhibitor
Sensitive
:
D
MUC4 expression
HER2 Positive Breast Cancer
MUC4 expression
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki + INB03
Sensitive: D – Preclinical
fam-trastuzumab deruxtecan-nxki + INB03
Sensitive
:
D
fam-trastuzumab deruxtecan-nxki + INB03
Sensitive: D – Preclinical
fam-trastuzumab deruxtecan-nxki + INB03
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login